Concepedia
Statistics
Publications
16
Citations
779
H-Index
13
Active since
1993
Affiliations
University of California, Davis(Current)
Palmetto Hematology Oncology
University of California Davis Medical Center
Qansy Salako is an author at University of California, Davis specializing in radionuclide therapy, medicine, and oncology.
Publications per year
1993–1999
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
Gerald L. DeNardo, Sally J. DeNardo, D S Goldstein et al. · Journal of Clinical Oncology · 1998 · 182 citations
Medicine, Nuclear Medicine, Oncology +17
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
Sally J. DeNardo, Elissa L. Kramer, Robert T. OʼDonnell et al. · PubMed · 1997 · 84 citations
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
Sally J. DeNardo, Gerald L. DeNardo, David L. Kukis et al. · PubMed · 1999 · 65 citations
Medicine, Oncology, Pharmacokinetics +17
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates
David L. Kukis, Habibe Diril, Douglas P. Greiner et al. · Cancer · 1994 · 62 citations · Full text
Pharmacy, Biochemistry, Immunology +16
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Gerald L. DeNardo, Sally J. DeNardo, David L. Kukis et al. · PubMed · 1998 · 60 citations
1–5 of 16